Alembic Eyes 40% Growth with 30 New US Drug Launches

Alembic Pharmaceuticals is banking on its upcoming US drug launch pipeline to sustain strong growth as competition and pricing pressure reshape the generics market.

The Vadodara-based pharmaceutical company plans to introduce around 30 products in the US over the next 18 months, targeting 40 percent growth in FY27.

However, the expiry of Bosutinib exclusivity this month creates a significant transition for its US business.

Managing Director Pranav Amin remains confident that new launches, differentiated products and stronger pipeline execution can help Alembic maintain its growth momentum.

Alembic Plans 30 US Drug Launches to Sustain Growth

Alembic's US formulations business grew 77 percent during the September quarter, supported by a strong base business and contributions from new launches. The base business expanded 23 percent, while Bosutinib, an oncology drug, remained a major growth contributor before its exclusivity expired. The company expects its upcoming US drug launch pipeline to offset the impact of this transition and support its FY27 growth target.

Key developments include:

• Around 30 planned US launches over the next 18 months.
• Approximately one-quarter of these products carry NCE-1 shared exclusivity or first-to-file status.
• Management expects to sustain 40 percent US growth despite a higher comparison base in FY27.

Amin said Alembic retains a decent product portfolio and expects the business to continue growing beyond FY27.

Also Read: India's 30% Anti-Cancer Drug Margin Cap: What It Means for Pharma

Complex Generics and Injectables Support Future Expansion

Alembic is shifting research and development towards complex therapeutics to reduce dependence on commoditized generics. Its strategy includes injectables, oncology products, and Day-1 and NCE-1 filings.

The company recently signed a licensing agreement with DifGen to in-license approximately 20 complex products, including injectables and transdermal patches. These products could strengthen differentiation and expand its future US drug launch opportunities.

Other business developments include:

• India business growth of 14 percent during the September quarter.
• API segment growth of 39 percent, supported by contract manufacturing deals.
• Chronic therapies accounting for 55 percent of its portfolio.

Pricing pressure, competition, and slower international growth remain challenges. Ultimately, successful pipeline execution and timely US drug launch delivery will determine whether Alembic can sustain its ambitious growth target.